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Elucidating the impact of excipient variability on oral product performance in a 22 
biopharmaceutical perspective would be beneficial and allow excipient implementation on 23 
Quality by Design (QbD) approaches. The current study investigated the impact of varying 24 
viscosity of binders (hypromellose (HPMC)) and superdisintegrants (sodium starch glycolate 25 
(SSG)) and particle size distribution of lubricants (magnesium stearate (MgSt)) on the in vitro 26 
dissolution of a highly and a poorly soluble drug from immediate release formulations. 27 
Compendial (pharmacopoeia buffers) and biorelevant (media simulating the gastrointestinal 28 
fluids) media and the USP 2 and USP 4 apparatuses were used to assess the exerted excipient 29 
effects on drug dissolution. Real-time dissolution UV imaging provided mechanistic insights 30 
into disintegration and dissolution of the immediate release formulations. Varying the viscosity 31 
type of HPMC or SSG did not significantly affect drug dissolution irrespective of the 32 
compound used. Faster drug dissolution was observed when decreasing the particle size of 33 
MgSt for the highly soluble drug. The use of real-time dissolution UV Imaging revealed the 34 
influential role of excipient variability on tablet disintegration, as for the highly soluble drug, 35 
tablets containing high viscosity HPMC or low particle size MgSt disintegrated faster as 36 
compared to the control tablets while for the poorly soluble drug, slower tablet disintegration 37 
was observed when increasing the viscosity of the HPMC as compared to the control tablets. 38 
Changes in drug dissolution when varying excipients may be anticipated if the excipient change 39 
has previously affected drug solubility. The use of multivariate data analysis revealed the 40 
influential biopharmaceutical factors such as critical excipient types/properties, drug aqueous 41 
solubility, medium/hydrodynamic characteristics affecting the impact of excipient variability 42 
on in vitro drug dissolution. 43 
Keywords: excipient variability; HPMC; sodium starch glycolate; magnesium stearate; in vitro 44 




1. Introduction 47 
Introduction of the Quality by Design (QbD) initiative in the pharmaceutical industry is 48 
crucial for the development of robust manufacturing processes and the safety of final products. 49 
The requirements of a final dosage form are identified from a patient perspective and are 50 
translated into critical quality attributes (CQAs). Critical material attributes (CMAs) of input 51 
raw materials and critical process parameters (CPPs) for the manufacture of dosage forms must 52 
then be controlled to ensure that the CQAs are delivered [1]. Control strategies and design 53 
spaces are built to cope with the variability and/or variation of the factors affecting product 54 
manufacturing or performance [2]. Implementation of QbD approaches in the traditional 55 
pharmaceutical development can prevent batch failures and improve cost effectiveness due to 56 
the scientific understanding and control of the manufacturing processes [1]. The principles of 57 
QbD could, as well, be beneficial in emerging technologies, such as continuous manufacturing, 58 
as they will allow the identification, control and monitoring of the continuous dynamic 59 
processes during development [3]. 60 
Dissolution testing can be a powerful tool in the QbD concept providing information on the 61 
critical factors that can affect oral drug absorption [4]. Quality control dissolution methods can 62 
assess inter-batch consistencies, as they are developed to discriminate the critical factors 63 
(CMAs or CPPs) affecting the performance of final dosage forms [5]. The development of 64 
biorelevant dissolution methods demonstrates the ability of dissolution testing to delineate the 65 
impact of physiological conditions (pH of the medium, presence of solubilizing components, 66 
fasted vs fed state, hydrodynamics) on product performance [6]. Prediction of the in vivo 67 
product performance through dissolution tests (clinically relevant dissolution methods) can be 68 
achieved with the development of in vitro-in vivo correlations (IVIVC) that will assist in the 69 
identification of CQAs and substitute in vivo bioequivalence studies [4, 7]. Media (compendial: 70 
pharmacopeia buffers, biorelevant: mimicking the composition of the gastrointestinal fluids) 71 
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[8, 9] and apparatus (USP 1: basket assembly, USP 2: paddle assembly, USP 3: reciprocating 72 
cylinder, USP 4: flow-through cell) [10] able to simulate gastrointestinal conditions and predict 73 
oral product performance have been developed to serve the purposes of the dissolution 74 
methods. The biorelevance of dissolution methods in terms of in vivo performance is still 75 
challenging [11]. The compendial dissolution apparatuses cannot entirely reflect the 76 
complexity of the gastrointestinal tract in terms of hydrodynamics [5]. Generated artefacts due 77 
to the dissolution method, e.g., coning in the bottom of the dissolution vessel in the USP 2 78 
apparatus in presence of insoluble excipients [5] or the evaluated dosage forms sticking to 79 
surfaces or floating [12], may demonstrate profiles without biopharmaceutical relevance. The 80 
risks of over or under discrimination between products are challenging and clinically relevant 81 
dissolution methods, linking in vitro to in vivo performance, may be required to properly assess 82 
the effects of product variation on product performance [5]. Recent advances in real-time 83 
dissolution UV-imaging techniques have allowed the spatial and temporal visualization of the 84 
dissolution phenomena of APIs from compacts [13-15] or dosage forms [16], the role of 85 
excipients [17-19] and physiological conditions (pH [20, 21], hydrodynamics [17], biorelevant 86 
media [22]) on drug dissolution. These techniques could provide additional information on the 87 
mechanisms through which critical factors can affect in vitro drug dissolution. 88 
The critical role of excipient presence, variability (changes in material properties) or 89 
variation (changes in amount) on product quality is highlighted [23, 24] and it is recognized 90 
that the effects of excipients on product performance relate to several biopharmaceutical factors 91 
(gastrointestinal conditions, drug physicochemical properties) [25]. Several studies have 92 
shown that changes in the physical or chemical excipient composition, changes in the amount 93 
of excipient used and excipient interchangeability affected in vitro drug dissolution [25]. 94 
Increasing the viscosity type of cellulosic polymers (hydroxypropylcellulose (HPC), 95 
hydroxypropylmethylcellulose (HPMC)) resulted in slower theophylline release from 96 
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hydrophilic matrix tablets (USP 2 apparatus, 900 mL distilled water, 37 °C, 50 rpm and 100 97 
rpm for tablets containing HPC and HPMC, respectively) [26, 27]. Pronounced delay in the 98 
dissolution and release of theophylline from matrix tablets (USP 1 apparatus, distilled water, 99 
37 °C, 100 rpm) containing magnesium stearate (MgSt) was observed with increasing excipient 100 
level (1% w/w – 5% w/w) [28]. The dissolution profiles of hydrochlorothiazide from tablets 101 
containing crospovidone brands from two different suppliers (USP 1 apparatus, 900 mL 0.1 N 102 
HCl pH 1, 37 °C, 100 rpm) were not similar due to the differences in excipient porosity, despite 103 
the interchangeability of the studied brands [29, 30]. The implications of excipients on in vivo 104 
product performance have been highlighted, as changes in drug bioavailability and 105 
bioinequivalence within products have been attributed to excipient presence [31]. 106 
Bioequivalence studies failed to show similarity between innovator and generic products of 107 
alendronate, as the presence of sodium lauryl sulfate in the generic product resulted in a 5-fold 108 
increase in drug bioavailability [31]. International associations and regulatory agencies are 109 
strictly addressing the issue of excipient variability on product performance [32]. Evaluation 110 
of the significance of excipient changes [33] and excipient functionality [34, 35] on drug 111 
dissolution is needed. Scientific justification that excipient changes will not affect formulation 112 
quality and performance is required by regulatory agencies [36]. Scale-up or post approval 113 
excipient changes may or may not require in vitro dissolution documentation according to 114 
excipient type or amount and drug characteristics (Level 1: deletion of colouring/flavouring 115 
agents or changes in excipient amount within specified limits do not require additional 116 
dissolution documentation, Level 2: changes in excipient technical grades or excipient amount 117 
greater than the Level 1 limits require addition dissolution justification). Failure to meet in vitro 118 
dissolution criteria requires full dissolution and bioequivalence documentation (Level 3) [36]. 119 
Excipient changes when requesting biowaivers are also considered as excipients may affect 120 
drug absorption [37, 38]. 121 
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The aim of this study was to identify the impact of excipient variability on in vitro drug 122 
dissolution in a biopharmaceutical perspective. Excipient variability was assessed by obtaining 123 
variants in critical material attributes of binders (hypromellose (HPMC) – viscosity type), 124 
superdisintegrants (sodium starch glycolate (SSG) – viscosity type) and lubricants (magnesium 125 
stearate (MgSt) – particle size distribution (PSD)) and producing immediate release 126 
formulations (control and variant tablets) for a highly and a poorly soluble model compound 127 
using wet granulation. Dissolution studies were performed in compendial and biorelevant 128 
media with the USP 2 and USP 4 apparatus. Real-time dissolution UV imaging was also 129 
performed to provide a mechanistic understanding of the dissolution processes of the 130 
manufactured tablets. Multivariate data analysis (Partial Least Squares (PLS)) was used to 131 
understand the effects of certain variables (excipient critical material attributes, drug aqueous 132 
solubility, medium and hydrodynamic characteristics) on the impact of excipients on drug 133 
dissolution. 134 
2.  Materials and Methods 135 
2.1. Materials and Instrumentation 136 
2.1.1. Materials 137 
APIs: Paracetamol (PRC) and carbamazepine (CBZ) were obtained from Fagron, UK. 138 
Excipients: mannitol (Pearlitol 160C, Roquette Frères, France), microcrystalline cellulose 139 
(Avicel PH101, FMC Biopolymer, USA), hypromellose (HPMC) [HPMC 2910, 5 cP 140 
(Methocel E5) and HPMC 2910, 15 cP (Methocel E15), Dow Chemical Company, USA)], 141 
sodium starch glycolate (SSG) (Glycolys and Glycolys LV, Roquette Frères, France), 142 
magnesium stearate (MgSt) (Ligamed MF-2-V and Ligamed MF-3-V, Peter Greven, 143 
Netherlands) were purchased from the specified sources. Chemicals: hydrochloric acid 36.5–144 
38%, HPLC grade methanol, pepsin (from porcine) were obtained from Sigma-Aldrich (UK). 145 
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Maleic acid, sodium chloride, sodium hydroxide, potassium phosphate monobasic were 146 
obtained from Fisher Scientific (UK). Sodium taurocholate (Prodotti Chimici Alimentari 147 
S.P.A., Italy), egg lecithin – Lipoid EPCS (Lipoid GmbH, Germany), were obtained from the 148 
sources specified. Water was ultra-pure (Milli-Q) laboratory grade. Filters: Cronus 13 mm 149 
regenerated cellulose (RC) syringe filters 0.45 μm were purchased from LabHut (UK), 150 
Whatman® 24 mm glass fibre filters 0.7 μm pore size (GF/F) and Whatman® 24 mm glass 151 
microfibre filters 2.1 μm pore size (GF/D) were purchased from Fischer Scientific (UK). Glass 152 
wool was obtained from Sigma Aldrich (UK). 153 
2.1.2. Instrumentation 154 
Equipment used included: a Pharmatech drum blender (Pharmatech, UK), a ConsigmaTM-155 
1 granulator (GEA Pharma Systems, Belgium), a Quadro Comill 193 (Ytron Quadro Ltd, UK) 156 
equipped with a 1397 μm screen, a Turbula blender Type T2F (GlenMills Inc., USA), a Kilian 157 
Styl’One Evo press (Romaco Kilian, Germany) equipped with 11 mm normal ankle cave 158 
punches, a Mettler Toledo SR32001 DeltaRange balance (Mettler Toledo, Switzerland), digital 159 
calipers (Mitutoyo Ltd, UK), a Sotax HT100 automated tablet tester (Sotax, Switzerland), a 160 
Erweka ZT70 disintegration tester (Erweka GmbH, Germany), a VK-7000 Vankel® USP 2 161 
apparatus (Vankel® dissolution system, USA) connected with an VK-750D external heating 162 
circulator (Vankel®, USA), a DFZ720 Erweka® flow-through dissolution tester connected to 163 
a HKP 720 Erweka® piston pump (Erweka GmbH, Germany), an SDi2 surface dissolution UV 164 
imaging system (Pion Inc., USA), a UV-Vis spectrophotometer (Ocean Optics, USA), a Buchi 165 
R114 Rotavapor (Buchi, Switzerland), a Mettler Toledo SevenCompact S210 pH meter 166 
(Mettler Toledo, Switzerland), an Agilent Technologies 1100 series HPLC system, (quaternary 167 
pump (G1311A), autosampler (G1313A), thermostatted column compartment (G1316A), 168 
diode array detector (G1329A) and a Chemstation software (Agilent Technologies, USA),  169 
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2.2.  Methods 170 
2.2.1. Tablet manufacturing 171 
Tablets were produced to assess the influence of increasing the viscosity of HPMC 172 
(HPMCH variant), decreasing the viscosity of SSG (SSGL variant) and decreasing the particle 173 
size of MgSt (MgStL variant). The composition of the manufactured tablets is presented in 174 
Table 1. The batch size of the blend was 400g – 680g depending on the availability of the API. 175 
Granules containing drug, mannitol, microcrystalline cellulose, HPMC, SSG were prepared by 176 
twin screw granulation. Drug and excipients were mixed for 30 min at 25 rpm (mixing order: 177 
Pearlitol, Glycolys, Methocel, API, Avicel). Wet granulation was performed using distilled 178 
water as the granulation liquid, with a screw speed at 900 rpm, powder mass flow at 15 kg/h 179 
and liquid mass flow at 100 g/min (granulation liquid dosed in-line via a port in the barrel of 180 
the twin screw granulator). Granules were collected and left to dry overnight at 60 °C (at a 181 
drying end point of < 2% moisture loss on drying). Granules were milled at 2000 rpm with a 182 
1.4 mm mesh to improve granule flow and filling in the die for compression. Granules were 183 
lubricated with MgSt for 3 min with a speed of 30 rpm. Tablets were manufactured at a 184 
compression force of 20 kN for PRC and 15 kN for CBZ at a speed of 25 rpm. For each of the 185 
PRC or CBZ batches (control and variant tablets), 200 tablets were produced. 186 
2.2.2. Tablet characterization 187 
The manufactured tablets were characterized in terms of tablet mass, thickness, width, 188 
hardness and disintegration time. Tablet mass was measured using an analytical balance. Tablet 189 
thickness and width were measured using digital callipers. Tablets hardness was assessed using 190 
an automated tablet tester. Ten tablets from each of the PRC and CBZ batches (control and 191 
variant tablets) were used to calculate the mean tablet mass (mg) ± standard deviation (SD), 192 
mean tablet thickness (mm) ±SD, mean tablet width (mm) ±SD and mean tablet hardness (N) 193 
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±SD. Tablet disintegration time was measured without discs at 37°C using distilled water as 194 
the immersion fluid [39]. The disintegration time (time at which tablet particles passed through 195 
the mesh at the bottom of the basket) was automatically recorded. The mean disintegration time 196 
(min) ±SD for 6 PRC and 3 CBZ tablets (for each control and variant tablets) was determined. 197 
2.2.3. Media used for dissolution studies 198 
Compendial media (0.1 N HCl pH 1, phosphate buffer pH 6.8) were prepared according to 199 
the method described in the European Pharmacopeia [40]. Fasted State Simulated Gastric Fluid 200 
(FaSSGF) and Fasted State Simulated Intestinal Fluid (FaSSIF-V2) were prepared as described 201 
by Jantratid et al. [41]. 202 
2.2.4. In vitro dissolution studies 203 
2.2.4.1. USP 2 apparatus 204 
Experiments were performed at 37 °C using 500 mL of dissolution medium (compendial 205 
or biorelevant). The rotational speed of the paddle was set at 50 rpm, in order to provide 206 
adequate discrimination between the studied control and variant tablets [42]. Sample aliquots 207 
of 3 mL were withdrawn at 5, 10, 15, 20, 30, 45, 60 min for PRC and 5, 10, 15, 20, 30, 45, 60, 208 
90, 120, 180, 240 min for CBZ, filtered through RC 0.45 μm pore size filters, diluted with the 209 
corresponding medium (if needed) and analysed by HPLC. Filter adsorption studies were 210 
performed in triplicate for each drug prior to the experiments and confirmed no adsorption 211 
issues for the studied drugs on the filters used. At each sampling time point the volume of the 212 
withdrawn samples was replaced with fresh corresponding dissolution medium. All 213 
experiments were performed in triplicate. 214 
2.2.4.2. USP 4 apparatus 215 
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The USP 4 apparatus was further selected to assess the performance of the studied tablets 216 
as it represents a more biorelevant setup mimicking the in vivo hydrodynamic conditions [10]. 217 
Experiments were performed at 37 °C using the Ø 12 mm (small) and Ø 22.4 mm (large) cells 218 
for PRC and the Ø 12 mm (small) cells for CBZ. A 5 mm-size ruby bead was positioned in the 219 
tip of the cell and 1g (small cells) or 6 g (large cells) of 1 mm-sized glass beads were added. 220 
On the top of the cell a GF/F filter was placed for PRC and one GF/F filter, 0.15 g of glass 221 
wool and one GF/D filter were placed for CBZ. The flow rate was set at 4 mL/min. For PRC 222 
the closed-loop configuration was used. Samples of 3 mL volume were withdrawn at 5, 10, 15, 223 
20, 30, 45, 60 min, diluted with the corresponding medium and analysed by HPLC. At each 224 
sampling time points the volume of the withdrawn samples was replaced with fresh 225 
corresponding dissolution medium. For CBZ the open-loop configuration was used in order to 226 
achieve sink conditions. Dissolution samples were collected in a volumetric cylinder, samples 227 
were diluted with the corresponding medium and analysed by HPLC. Cylinders were 228 
exchanged at 5, 10, 15, 20, 30, 45, 60, 90, 120, 180 and 240 min after the beginning of the 229 
experiment. All experiments were performed in triplicate. 230 
2.2.4.3. Real – time dissolution UV imaging 231 
Surface dissolution UV imaging was performed using the SDi2 instrument with a USP 4 232 
type flow-cell (cell volume: 60.3 mL, cell diameter: 28 mm, effective imaging area: 28 x 24 233 
mm2). Dissolution studies of the PRC and CBZ tablets (control and variant tablets) were 234 
conducted at a flow rate of 6.16 mL at 37 °C using 0.1 N HCl pH 1 as dissolution medium for 235 
20 min. This flow rate was selected to simulate the linear velocity (1 cm/min) in the USP 4 236 
(large cells) when operating at 4 mL/min. Dual-wavelength imaging was performed using two 237 
Light Emitting Diodes (LEDs) at 300 and 520 nm for PRC and 320 and 520 nm for CBZ. Drug 238 
quantification was assessed by monitoring drug concentrations of the effluent at 1 min intervals 239 
using a photodiode array UV-Vis. Drug quantification in the effluent was made based on 240 
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calibration curves (calibration ranges: 2 – 50 μg/mL for PRC, 20 – 150 μg/mL for CBZ). Real-241 
time surface dissolution UV images showing the disintegration and dissolution phenomena of 242 
the studied tablets were obtained and processed using the SDi2 analysis software v. 3.0.22 243 
(Pion Inc, USA). All experiments were performed in triplicate. 244 
2.2.5. Chromatographic conditions 245 
Drug quantification in the dissolution samples was performed by HPLC-UV. Analytical 246 
HPLC procedures were modifications of already published methods for PRC [43] and CBZ 247 
[44]. A reversed-phase Spherisorb (Waters) C18 column (250 × 4.6 mm, 5 μm) was used for 248 
both drugs. For PRC, the mobile phase consisted of methanol and water 20:80 (v/v) and the 249 
temperature was kept constant at 20 °C. The injection volume was 20 μL and the detection 250 
wavelength was at 257 nm. For CBZ, the mobile phase was composed of methanol and water 251 
60:40 (v/v) and the temperature was kept constant at 25 °C. The injection volume was 100 μL 252 
and the detection wavelength was at 285 nm. The flow rate was set at 1 mL/min for both drugs. 253 
The elution times were 6 min and 4 min for PRC and CBZ, respectively. Drug quantification 254 
was made based on calibration curves. Standards were formulated from concentrated stock 255 
solution of drug dissolved in MeOH (PRC: 2 mg/mL, CBZ: 1 mg/mL). The range of the 256 
calibration curves were 10 – 200 μg/mL and 10 -150 μg/mL for PRC and CBZ, respectively. 257 
2.2.6. Treatment of in vitro dissolution data 258 
The cumulative % of drug dissolved in the USP 2 apparatus and USP 4 apparatus – closed 259 
loop configuration was calculated based on drug quantification from the analytical method 260 
(HPLC) and the amount of drug in the manufactured tablets. The cumulative % of drug 261 
dissolved in the USP 4 apparatus - open loop configuration and the effluent analysis of the 262 
SDi2 was calculated based on drug quantification from the analytical method (HPLC for the 263 
samples obtained with the USP 4 apparatus, spectrophotometry for the effluents obtained from 264 
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the SDi2), the flow rate of the system and the amount of drug in the manufactured tablets. The 265 
dissolution profiles depicting the cumulative % of drug dissolved from the control and variant 266 
tablets as a function of time were generated using Spotfire 7.10.1 (TIBCO software Inc, USA). 267 
The area under the curve (AUC) of the dissolution profiles, calculated using the method of 268 
trapezoids, was used for the characterization of drug dissolution. In cases where the dissolution 269 
profiles reached a plateau level, the AUC of the dissolution profiles was calculated up to the 270 
time corresponding to the first experimental datum after the 85% of drug dissolution for both 271 
the control and variant tablets in each medium [45]. In cases where the dissolution profiles did 272 
not reach a plateau level, the AUC of the dissolution profiles was calculated up to the last 273 
experimental time point. The Relative Effect (𝑅𝐸𝐴𝑈𝐶) of each excipient variant on the AUCs 274 
of the dissolution profiles was calculated based on Equation 1: 275 
𝑅𝐸𝐴𝑈𝐶 =  
(𝐴𝑈𝐶𝑇− 𝐴𝑈𝐶𝑅)
𝐴𝑈𝐶𝑅
 𝑥 100 equation 1 276 
where 𝐴𝑈𝐶𝑅 and 𝐴𝑈𝐶𝑇 are the areas under the curve of the dissolution profiles of the 277 
reference and test product, respectively. Two sets of comparisons were performed. In the first 278 
set (set 1), the differences in drug dissolution within the studied tablets in each medium were 279 
examined taking the AUCs of the dissolution profiles of the control and variant tablets as 280 
reference and test dissolution profiles, respectively. In the second set (set 2), differences in 281 
drug dissolution within acidic and basic conditions (in compendial and biorelevant media) for 282 
each tablet batch were investigated taking the AUCs of the dissolution profiles in acidic and 283 
basic conditions as the reference and test dissolution profiles, respectively. The relationship 284 
between the impact of excipient variability on dissolution performance and drug solubility in 285 
the studied media was investigated using the REs of excipients on AUCs of the dissolution 286 
profiles and the relative increase or decrease in drug solubility by the studied excipients ; the 287 
solubility data of PRC and CBZ (previously published) in presence of 2% HPMC [46], 5% 288 
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SSG [47] or 2% MgSt [48] were used. The Relative Effect (𝑅𝐸𝑠) of each excipient on drug 289 
solubility were calculated based on Equation 2: 290 
𝑅𝐸𝑠 =  
(𝑆−𝑆𝑟)
𝑆𝑟
 𝑥 100  equation 2 291 
where 𝑆 and 𝑆𝑟 denote drug solubility in presence of the excipient brand of the variant 292 
tablets and in presence of the corresponding excipient brand in the control tablets. The risk 293 
assessment of the impact of excipients on drug dissolution or drug solubility was evaluated by 294 
setting reference range criteria of -20% - 25% [49] on the REsAUC or REsS (this range was 295 
selected as a similar range is set in order to assess differences in drug exposure after oral 296 
administration; i.e. in bioequivalence studies). REsAUC or REsS outside these values (REAUC or 297 
REsS < -20% or REAUC or REsS > 25%) were considered critical for oral drug performance. 298 
2.2.7. Statistical analysis of in vitro dissolution data 299 
2.2.7.1. In vitro dissolution profile comparisons 300 
Dissolution profile comparisons were performed with the use of the f2 (similarity factor) 301 
assuming the dissolution profiles of the control and variant batches as the reference and test 302 
dissolution profiles, respectively, according to Equation 3 [45]: 303 
𝑓2 =  50 𝑥 log{ [1 + (
1
𝑛
) ∑ (𝑅𝑡 − 𝑇𝑡)2𝑛𝑡=1 ]
−0.5
 𝑥 100} equation 3 304 
where 𝑅𝑡 and 𝑇𝑡 are the reference and test % cumulative profiles at time t, respectively and 305 
𝑛 is the number of sampling points. Evaluation of f2 was considered up to the time 306 
corresponding to the first experimental datum after the 85% of drug dissolution of both the 307 
control and variant tablets in each medium [45]. In cases where 85% of drug dissolution was 308 
not reached at the end of the experiment, dissolution profile comparisons were performed up 309 
to the last experimental time point. Mean data sets were used as the coefficient of variation was 310 
less than 20% and 10% for early (up to 15 min) and late time points, respectively. Differences 311 
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between the dissolution profiles of the test and the reference product were identified setting a 312 
10% difference (f2 < 50). 313 
2.2.7.2. Multivariate data analysis of in vitro dissolution data 314 
Excipient REs on drug dissolution were correlated to excipient critical material attributes 315 
(viscosity for HPMC and SSG, PSD for MgSt), drug aqueous solubility (Drugaq.sol.), medium 316 
properties (gastric, intestinal) and hydrodynamics (USP apparatus) by partial least squares 317 
(PLS) regression using the XLSTAT software (Microsoft, USA). Two models for the REs of 318 
excipients on the AUCs of the dissolution profiles in compendial media (Model 1) and 319 
biorelevant media (Model 2) were constructed. The evaluated variables for both models were 320 
all categorical and are presented in Table 2. Excipient REs on the AUCs of the dissolution 321 
profiles (set 1, section 2.2.6.) were used as the response. The selected interaction terms included 322 
each excipient variant combined with each drug aqueous solubility (Drugaq.sol.), medium 323 
property (gastric, intestinal) and hydrodynamic characteristics (USP apparatus). The generated 324 
PLS models were assessed in terms of goodness of fit (R2) and goodness of prediction (Q2) 325 
[successful models: Q2 > 0.5 [50] and R2 and Q2 values with a difference not greater than 0.2 - 326 
0.3 [51]]. The number of PLS components (lines on the X-space which best approximate and 327 
correlate with the Y-vector) was based on minimum predictive residual sum of squares 328 
(PRESS) [51]. From the available components the one at which Q2 reached its maximum value 329 
was selected [52]. Standardized coefficients were used to show the direction (positive or 330 
negative) and extent of each variable on the response. The significance of the variables was 331 
assessed by the variable influence on projection (VIP) value. The significance of the variables 332 
was assessed by the variable influence on projection (VIP) value. VIP values > 0.8 were 333 
considered as moderately influential in the model while VIP values > 1 were considered the 334 
most influential in the model [51]. A 95 % confidence interval was used. 335 
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3. Results and Discussions 336 
3.1. Tablet characterization 337 
The properties of the manufactured PRC and CBZ tablets are presented in Table 3. Tablets 338 
of approximately 500 mg mass, 5.5 mm thickness and 11.0 mm diameter were produced 339 
irrespective of model compound or variant used. Comparison of the control tablets of PRC and 340 
CBZ showed lower hardness and faster disintegration time for the CBZ control tablets which 341 
could be explained by the lipophilic nature of CBZ (log P = 2.45 [53], as incorporation of 342 
lipophilic components may result in the production of softer tablets. The PRC and CBZ 343 
containing tablets were produced using different compaction forces (section 2.2.1). Evaluation 344 
of the impact of different compaction forces on tablet hardness revealed similar qualitative 345 
differences for the CBZ tablets compressed at 20 kN compaction force as compared to the CBZ 346 
tablets used in this study (compressed at 15 kN) (data not shown). Therefore, it is unlikely that 347 
the different compaction forces used for the tablets of the two drugs have affected the outcomes 348 
of the study. The choice of wet granulation using the same experimental conditions for the 349 
highly and poorly soluble drugs may have affected granule properties which in turn influence 350 
tablet disintegration and drug dissolution. The poor wetting properties of poorly soluble 351 
compounds may affect drug distribution within the granules. Hydrophilic excipients are 352 
preferentially nucleated in the granule core while the drug is distributed around this core in a 353 
process of layering (marble formation) [54, 55]. This may have contributed to the reduced 354 
tablet hardness of the CBZ tablets. The potential higher porosity of granules comprising the 355 
poorly soluble drug, as compared to highly soluble compounds, due to their different wetting 356 
may also have contributed to the faster disintegration and drug dissolution of the CBZ tablets 357 
[54]. For PRC, the HPMCH variant tablets (high HPMC viscosity) exhibited lower hardness 358 
and faster disintegration compared to the control tablets (low HPMC viscosity), as densification 359 
of HPMC reduces with increasing excipient viscosity [56]. For CBZ, the tablet hardness of the 360 
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control and the HPMCH variant tablets were similar. The slower disintegration of the HPMCH 361 
variant tablets compared to the control tablets may be explained by the higher viscosity of the 362 
HPMCH variant [57]. A reduction in granule porosity, when increasing binder viscosity, due to 363 
stronger liquid bonds may have also contributed to the slower tablet disintegration observed 364 
[58]. The SSGL variant tablets (low SSG viscosity) were softer as compared to the control 365 
tablets (high SSG viscosity) in the case of PRC. As a higher degree of crosslinking between 366 
the hydroxyl groups of SSG reduces the solubility of the polymer [59, 60] the lower tablet 367 
hardness may be attributed to the decreased polymer hydrophilicity or the formation of less 368 
hydrogen bonds in the SSG variant as compared to the control tablets. Breakage of the 369 
crosslinking bonds for SSG during high-shear granulation have been reported, and it was 370 
demonstrated that high viscosity (low crosslinked brands) are most susceptible in breaking 371 
[61]. As the crosslinks are damaged, an increase in the viscosity of the slurry might be observed 372 
and SSG may act as a particle binder increasing granule agglomeration [61]. The 373 
aforementioned mechanism may also relate to the observed lower tablet hardness of the SSGL 374 
variant. Differences in tablet hardness between the control and SSGL variant tablets were not 375 
observed for CBZ, though. The poor wetting properties of CBZ may explain the absence of 376 
any effect on tablet hardness when varying SSG. Highly crosslinked SSG brands (low SSG 377 
viscosity) would be expected to lead to faster tablet disintegration due to the increased water 378 
uptake [62]. However, differences in tablet disintegration between the SSGL variant and control 379 
tablets were minor irrespective of model compound. The presence of 2% of MgSt may have 380 
affected the penetration rate of water into the tablets and diminish the differences in 381 
disintegration time between the studied SSG brands [59]. The MgStL variant (low MgSt particle 382 
size) produced softer tablets as compared to the control tablets (high MgSt particle size) for 383 
PRC as a result of the better lubrication efficiency of the lower particle size of the MgSt variant 384 
[63]. Lower particle size MgSt is expected to have higher specific surface area providing a 385 
17 
 
better coverage around the particles. This might lead to reduced interparticle bonding strength 386 
during compression, producing softer tablets. The faster disintegration of the MgStL variant 387 
tablets compared to the control tablets is attributed to its lower tablet hardness [64]. Although 388 
lower particle size MgSt may impair particle/granule/tablet wetting upon contact with the 389 
dissolution medium, the faster disintegration of the MgStL variant tablets as compared to the 390 
control batches suggests that in this case the impact of MgSt variability on tablet properties is 391 
more significant compared to its impact on particle wetting. No impact on the hardness and 392 
disintegration data were found when varying MgSt brand for CBZ. The observed differences 393 
in tablet hardness and tablet disintegration time between the control and the variant tablets can 394 
relate to the different properties of the drug substances and the amount of the drug in the tablet. 395 
Continuous twin screw wet granulation was selected as the tablet manufacturing process as 396 
this process potentially poses a higher level of challenge for excipient variability than others. 397 
The pharmaceutical industry is seeing a gradual move from batch to continuous manufacturing 398 
where understanding the impact of material attributes will be under greater scrutiny. Therefore, 399 
the study was designed to be representative of current and future industrially relevant 400 
manufacturing processes and the challenges that need to be addressed. In any drug product 401 
formulation and process, excipient variability has the potential to impact both 402 
processability/manufacturability as well as the properties of the intermediates (granules) and 403 
the final dosage form (tablet) performance and in most cases these effects are confounded. 404 
However, whilst several publications have reported on the effect of excipient variability on the 405 
wet granulation process and granule properties [65, 66], few have studied the impact on 406 
dissolution of the final dosage form and the biopharmaceutical implications therein. Therefore, 407 
this study attempted to systematically vary the material attributes but keep the manufacturing 408 
process as similar as possible and then study the impact on tablet performance. Although, the 409 
study lacks the in-depth characterization of the granules, tablets have been characterized 410 
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underlying the potential direct or indirect influence of excipient variability on the intermediate 411 
blends. 412 
3.2. In vitro dissolution studies 413 
Several dissolution methods were selected to assess the impact of hydrodynamics on 414 
product performance when varying excipients and discriminatory capability to varying degrees 415 
was expected based on the dissolution methods. Following the principles of selecting 416 
dissolution methods with adequate discriminatory power, the setups were chosen to ensure a 417 
gradual dissolution profile using appropriate time points and achieving the 85% of drug 418 
dissolution [11]. The USP 2 apparatus was selected, initially, as it currently constitutes the most 419 
commonly used setup in quality control tests [5]. A low agitation speed (50 rpm) was selected 420 
as it has already been demonstrated that increased agitation rates (>75 rpm) compromise the 421 
discriminatory power of the dissolution method [42]. Dissolution media were selected to cover 422 
the physiological pH ranges and expected to reveal differences in the behaviour of ionizable 423 
excipients [e.g., MgSt (weak acid) which is known to induce pronounced delays in drug 424 
dissolution in acidic media due to its conversion to stearic acid [67]; SSG which is known to 425 
swell more extensively in basic compared to acidic media due to it ionization state [60]]. For 426 
the PRC tablets, further to the tablet characterization which demonstrated differences in tablet 427 
hardness and disintegration between the control and MgSt variant tablets, the USP 2 428 
experimental setup was expected to be adequate in discriminating the performance at least for 429 
the control and MgSt variant tablets. The USP 4 setups were further selected to provide a more 430 
biorelevant dissolution method with hydrodynamic patterns closer to the ones observed in vivo 431 
(based on Reynolds numbers [68]). For CBZ, the lack of sink conditions in the USP 2 apparatus 432 
was considered a drawback for adequate discrimination, hence the USP 4 apparatus in an open 433 
loop configuration was considered as a means to cope with this limitation. 434 
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3.2.1. Control Tablets 435 
3.2.1.1. Highly soluble drug (PRC) 436 
The dissolution profiles of PRC from the control and variant tablets in compendial and 437 
biorelevant media in the USP 2, USP 4 (small cells) and USP 4 (large cells) apparatuses are 438 
presented in Figure 1. The dissolution of PRC from the control tablets was complete in all 439 
experimental conditions. In the USP 2 apparatus, the 85% of drug dissolution was reached in 440 
20 min in 0.1 N HCl pH 1, phosphate buffer pH 6.8 and FaSSGF and in 15 min in FaSSIF-V2. 441 
The faster drug dissolution in FaSSIF-V2 can be explained by the presence of bile salts 442 
improving tablet wetting [8]. In the USP 4 apparatus, the 85% of drug dissolution from the 443 
control tablets was reached in 30 min in 0.1 N HCl pH 1, and in 20 min in phosphate buffer pH 444 
6.8, FaSSGF and FaSSIF-V2 when the small cells were used and in 30 min in all experimental 445 
conditions when the large cells were used. The hydrodynamic conditions differ between the 446 
two studied systems as turbulent flows prevail in the USP 2 apparatus [68] while a lower degree 447 
of turbulence or laminar flows exist in the USP 4 apparatus when glass beads are used [69]. 448 
The existence of turbulent or laminar hydrodynamic regimes are often based on the Reynolds 449 
number (ratio of inertial to viscous forces in the fluid) which relates to the fluid and linear 450 
velocities in the studied apparatuses and associates with the mass transfer rates [70]. High fluid 451 
velocities (corresponding to high Reynolds number) have been reported in the USP 2 apparatus 452 
(fluid velocity of 0.049 m/s from the top surface of the tablet [10]) while the laminar flows in 453 
the USP 4 apparatus results in low fluid velocities (low Reynolds numbers) [Ø 12 mm cells 454 
(small cells): 0.005 m/s, Ø 22.4 mm cells (large cells): 0.001 m/s [70]]. In the USP 4 apparatus, 455 
the lower linear velocities at equivalent volumetric flow rates in the large compared to the small 456 
cells relate to the increased cross-sectional area of the large cells [71]. Therefore, the slower 457 
drug dissolution in the USP 4 (small and large cells) compared to the USP 2 apparatus and the 458 
USP 4 apparatus (large cells compared to the small cells) is justified by the differences in fluid 459 
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velocities within the studied apparatuses (Reynold numbers in i. USP 2 apparatus: 5000-10000 460 
[68], ii. USP 4 apparatus – small cells: < 30, iii. USP 4 apparatus – large cells: < 8 in the USP 461 
4 apparatus – large cells) [72]. The relative effects (REs) of excipients on the AUCs of the 462 
dissolution profiles between acidic and basic conditions in compendial and biorelevant media 463 
are presented in Figure 2. The positive REsAUC in compendial media indicate faster drug 464 
dissolution in basic compared to acidic conditions. The presence of SSG or MgSt may lead to 465 
slower drug dissolution in acidic compared to basic conditions due to the reduced liquid water 466 
uptake by the neutral form of SSG [73] or the slower dissolution of stearic acid (dissociation 467 
product of MgSt) which limits drug dissolution [67] in acidic media. Differences in the REsAUC 468 
of excipients between acidic and basic media are less pronounced in biorelevant media, as the 469 
presence of the solubilizing components in these media facilitates tablet wetting and enhances 470 
drug dissolution [74]. 471 
3.2.1.2. Poorly soluble drug (CBZ) 472 
The dissolution profiles of CBZ from the control tablets in compendial and biorelevant 473 
media in the USP 2 and USP 4 (small cells) apparatuses are presented in Figure 3. In the USP 474 
2 apparatus, the dissolution of CBZ in the studied media was not complete (70% - 80% of drug 475 
dissolved at 4 hr), due to the lack of sink conditions. In the USP 4 apparatus, approximately 476 
85% of drug dissolution was reached after 4 hr from the control batch as sink conditions were 477 
achieved due to the open-loop configuration [69]. The REs of excipients on the AUCs of the 478 
dissolution profiles between acidic and basic conditions revealed slightly faster drug 479 
dissolution in basic conditions (2% < REsAUC < 10%) in the studied conditions (Figure 2). This 480 
indicates that the pH dependent performance of certain excipients (SSG or MgSt) will be less 481 
pronounced for poorly soluble as compared to highly soluble drugs. 482 
3.2.2. HPMCH variant 483 
21 
 
3.2.2.1. Highly soluble drug (PRC) 484 
Complete drug dissolution from the HPMCH variant tablets [containing the high viscosity 485 
HPMC brand (as compared to the low viscosity brand in the control tablets)] was observed in 486 
the studied experimental conditions (Figure 1). In the USP 2 apparatus, the 85% of drug 487 
dissolution from the HPMCH variant tablets was reached faster as compared to the control 488 
tablets in 0.1 N HCl pH 1, phosphate buffer pH 6.8 and FaSSGF (15 min vs 20 min for the 489 
HPMC variant tablets and control tablets, respectively). Differences in the time to reach 85% 490 
of drug dissolution between the HPMCH variant tablets and the control tablets were not 491 
observed in FaSSIF-V2 in the USP 2 apparatus and in all experimental conditions in the USP 492 
4 apparatus (small and large cells). The REs of excipients on the AUCs of the dissolution 493 
profiles between the HPMCH variant tablets and the control tablets are presented in Figure 4a. 494 
Positive REsAUC, corresponding to faster dissolution in the presence of the HPMCH variant 495 
were observed at all experimental conditions (0.6% < REs < 17%) apart from drug dissolution 496 
in biorelevant media in the USP 4 apparatus (small cells) (REsAUC of -3% and -2.3% in FaSSGF 497 
and FaSSIF-V2, respectively). The positive REsAUC indicated a slightly faster drug dissolution 498 
from the HPMCH variant tablets compared to the control tablets, most likely due to the faster 499 
tablet disintegration (Table 3). The dissolution profiles of the HPMCH variant tablets and the 500 
control tablets were similar (f2 > 50) in all experimental conditions (Table 4), indicating that 501 
varying HPMC viscosity type is not expected to be critical for the dissolution of highly soluble 502 
compounds from immediate release formulations. A dissolution medium effect in PRC 503 
dissolution from the HPMCH variant tablets was revealed, as drug dissolution was slightly 504 
faster in basic compared to acidic conditions in the compendial media (REsAUC of 24%, 18% 505 
and 6% in the USP 2, USP 4 (small cells) and USP 4 (large cells) apparatus, respectively) but 506 
not in the biorelevant media (Figure 4b). This differences with respect to PRC dissolution in 507 
basic as compared to acidic compendial media is attributed to the presence of SSG and MgSt 508 
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(as explained in 2.1.1.), therefore it is concluded that changes in the viscosity type of HPMC 509 
are not expected to affect the performance of other excipients in immediate release tablets. 510 
3.2.2.2. Poorly soluble drug (CBZ) 511 
Approximately, 80% (USP 2 apparatus) and complete (USP 4 apparatus) drug dissolution 512 
was reached in 4 hr from the HPMCH variant tablets (Figure 3), as sink conditions can be 513 
maintained in the USP 4 apparatus due the continuous flow of fresh dissolution medium, when 514 
the system operates in the open-loop configuration, compared to the USP 2 apparatus [69]. The 515 
REs on the AUCs of the dissolution profiles for the HPMCH variant tablets compared to the 516 
control tablets were minor in the USP 2 apparatus (-10% < REsAUC < 10%) and slightly positive 517 
in the USP 4 apparatus (6% < REsAUC < 13%) (Figure 4a). The dissolution profiles of the 518 
HPMCH variant tablets and control tablets were similar (f2 > 50) irrespective of medium or 519 
apparatus used (Table 4) revealing that varying HPMC viscosity type is not critical for the 520 
dissolution of this poorly soluble drug. Minor differences in drug dissolution in basic compared 521 
to acidic conditions (-0.5% < REsAUC < 15%) were observed for the HPMCH variant tablets 522 
only (Figure 4b).  523 
3.2.3. SSGL Variant 524 
3.2.3.1. Highly soluble drug (PRC) 525 
Drug dissolution was complete from the SSGL variant tablets [containing the low viscosity 526 
SSG brand (as compared to the high viscosity brand in the control tablets)] in all experimental 527 
conditions (Figure 1). Differences in the time to reach 85% of drug dissolution between the 528 
SSGL variant and the control tablets were observed only in the phosphate buffer pH 6.8 and 529 
FaSSGF in the USP 2 apparatus (15 min vs 20 min for the SSG variant and control tablets, 530 
respectively) and in 0.1 N HCl pH 1 in the USP 4 apparatus (large cells) (45 min vs 30 min for 531 
the SSG variant and control tablets, respectively). The REs of excipients on the AUCs of the 532 
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dissolution profiles between the SSGL variant tablets and the control tablets were minor in all 533 
experimental conditions (-10% < REsAUC < 10%) (Figure 5a) and dissolution profile 534 
comparisons (Table 4) revealed similarity between the dissolution profiles of the control and 535 
SSGL variant tablets (f2 > 50). The positive REs on the AUCs of the dissolution profiles from 536 
the comparisons of dissolution performance in the tested media indicated faster drug 537 
dissolution in basic compared to acidic conditions from the SSGL variant tablets in compendial 538 
media (Figure 5b). In compendial media, the REs on the AUCs of the dissolution profiles of 539 
the SSGL variant tablets between acidic and basic conditions (USP 2 apparatus: 15%, USP 4 540 
apparatus (small cells): 38%, USP 4 apparatus (large cells): 22%) were more pronounced as 541 
compared to the control tablets (USP 2 apparatus: 12%, USP 4 apparatus (small cells): 32%, 542 
USP 4 apparatus (large cells): 10%). These differences in drug dissolution between the SSGL 543 
variant tablets and control tablets may be attributed to the fast and extensive swelling of low 544 
viscosity SSG in basic media [62]. 545 
3.2.3.2. Poorly soluble drug (CBZ) 546 
The dissolution of CBZ from the SSGL variant tablets was incomplete (70% - 80%) and 547 
complete in the USP 2 and USP 4 apparatus, respectively (Figure 3). The REs on the AUCs of 548 
the dissolution profiles of the SSGL variant tablets were slightly positive in all experimental 549 
conditions (4.5 < REsAUC < 14%) apart from the case of drug dissolution in FaSSIF-V2 in the 550 
USP 2 apparatus (REAUC = -2.5%) (Figure 5a). The dissolution profiles of the SSGL variant 551 
tablets and the control tablets were similar in all experimental conditions (f2 > 50) (Table 4) 552 
indicating that varying SSG viscosity type is not significant for the dissolution of this poorly 553 
soluble drug. Slightly faster drug dissolution in basic compared to acidic conditions was 554 
observed (3% < REsAUC < 13%) except from the case of drug dissolution in biorelevant media 555 
in the USP 2 apparatus (REAUC = -6%) (Figure 5b).  556 
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3.2.4. MgStL Variant 557 
3.2.4.1. Highly soluble drug (PRC) 558 
Drug dissolution from the MgStL variant tablets [containing the low particle size MgSt 559 
brand (as compared to the high particle size brand in the control tablets)] was complete in all 560 
experimental conditions (Figure 1). The 85% of drug dissolution from the MgStL variant 561 
tablets was reached faster compared to the control tablets in compendial media and in FaSSGF 562 
in the USP 2 apparatus (15 min vs 20 min for the MgSt variant and control tablets, 563 
respectively). Although more effective lubricant grades would be expected to impede drug 564 
dissolution due to their effective lubrication efficiency, the observed faster drug dissolution is 565 
attributed to the production of porous tablets when varying MgSt (section 3.1). The time to 566 
reach 85% of drug dissolved was faster in 0.1 N HCl pH 1 (20 min vs 30 min for the MgStL 567 
variant and control tablets, respectively) and in phosphate buffer pH 6.8 and biorelevant media 568 
in the USP 4 apparatus (small cells) (15 min vs 20 min for the MgStL variant and control tablets, 569 
respectively). No differences in the time to reach 85% of drug dissolution were observed in 570 
FaSSIF-V2 (USP 2 apparatus) and for the experimental conditions utilizing the USP 4 571 
apparatus (large cells) between the MgStL variant and the control tablets. The REs of excipients 572 
on the AUCs of the dissolution profiles of the MgStL variant tablets compared to the control 573 
tablets were positive (8% < REsAUC < 41%), except from the case of drug dissolution in 574 
FaSSGF in the USP 4 apparatus (large cells) (REAUC = -0.7%) (Figure 6a). The positive 575 
REsAUC show faster drug dissolution most likely because the low particle size MgSt produced 576 
softer tablets with faster disintegration (Table 3). Drug dissolution from the MgStL variant 577 
tablets was significantly faster compared to the control tablets in phosphate buffer pH 6.8 (f2 = 578 
47.1), FaSSGF (f2 = 43.0) and FaSSIF-V2 (f2 = 41.2) in the USP 2 apparatus and in all the 579 
studied media in the USP 4 apparatus (small cell) (34.0 < f2 < 46.2) (Table 4) indicating the 580 
criticality of MgSt variability for the dissolution of highly soluble drugs. The significant 581 
25 
 
changes in drug dissolution between the control and MgStL variant tablets reveal the effects of 582 
the applied hydrodynamics on the impact of excipient variability on drug dissolution. 583 
Significant differences in drug dissolution were observed in the USP 2 apparatus and the USP 584 
4 apparatus (small cells) as compared to the USP 4 apparatus (large cells), as the discriminatory 585 
power of the dissolution method increased with increased fluid velocities or Reynolds numbers  586 
(explained in section 2.1.1). In compendial media, faster drug dissolution (6% < REsAUC < 587 
19%) from the MgSt variant tablets in basic compared to acidic conditions was observed 588 
revealing the pH-dependant performance of MgSt (Figure 6b). 589 
3.2.4.2. Poorly soluble drug (CBZ) 590 
Approximately, 70% - 80% (USP 2 apparatus) and 90% (USP 4 apparatus) of CBZ 591 
dissolved from the MgStL variant tablets (Figure 3). The REs on the AUCs of the dissolution 592 
profiles of the MgStL variant tablets compared to the control tablets were minor in all 593 
experimental conditions (-10% < REsAUC < 10%) (Figure 6a). Comparison of the dissolution 594 
profiles (Table 4) revealed that drug dissolution from the MgStL variant tablets was similar to 595 
the control tablets in all experimental conditions (f2 > 50). Slightly faster drug dissolution was 596 
observed under basic as compared to acidic conditions (2% < REsAUC < 12%) from the MgStL 597 
variant tablets (Figure 6b).  598 
3.3. Real time surface dissolution UV imaging 599 
The real-time dissolution UV visualization of the disintegration/dissolution phenomena for 600 
the PRC and CBZ tablets tested is presented in Figure 7. The UV Imaging showed that the 601 
PRC and CBZ control tablets were fully disintegrated at 16 min and 8 min, respectively. The 602 
dissolution profiles of the PRC and CBZ tablets are presented in Figure 8. Complete 603 
dissolution was not observed for any of the studied drugs. After 20 min, approximately 70% of 604 
PRC and 10% of CBZ dissolved from the control tablets. The faster dissolution of PRC as 605 
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compared to CBZ reflects the differences in the dissolution rates of highly and poorly soluble 606 
drugs, despite its slower disintegration in the SDi2 (as compared to CBZ) (Figure 7). In the 607 
case of PRC, tablet disintegration (13 min) (Figure 7) and drug dissolution (76% of drug 608 
dissolved at 20 min) were faster from the HPMCH variant tablets as compared to the control 609 
tablets (tablet disintegration at 16 min, 70% of drug dissolved at 20 min). These differences 610 
could be attributed to the lower tablet hardness of the HPMCH variant compared to the control 611 
tablets (Table 3). For CBZ, slower disintegration (17 min) and drug dissolution (7% of drug 612 
dissolved at 20 min) was observed from the HPMCH variant compared to the control tablets 613 
(tablet disintegration at 8 min, 10% of drug dissolved at 20 min). Changing the viscosity type 614 
of HPMC did not affected the hardness of CBZ tablets (as the impact of excipients on tablet 615 
hardness was pronounced for the highly soluble drug which inherently produced stronger 616 
tablets, Table 3). Therefore, the slower tablet disintegration and drug dissolution from the 617 
HPMCH variant compared to the control tablets could be attributed to the differences in the 618 
viscosity type of the used HPMC brands. The REs on the AUCs of the dissolution profiles 619 
revealed minor differences between the studied tablets for PRC (REAUC = -13%) and significant 620 
slower drug dissolution from the HPMCH variant tablets (REAUC = -48%) for CBZ due to the 621 
slower disintegration (Figure 7). The disintegration time of the SSGL variant tablets from the 622 
UV imaging study was similar to the control tablets for both PRC (16 min) and CBZ (9 min). 623 
Differences in drug dissolution when varying the SSG brand were not observed for any of the 624 
studied drugs (PRC: 70% of drug dissolved at 20 min, CBZ: 10% of drug dissolved at 20 min) 625 
and confirmed by the minor REs of excipients on the AUCs of the dissolution profiles (PRC: 626 
REAUC = -7%, CBZ: REAUC = 2%). Faster disintegration was observed for the MgStL variant 627 
tablets (11 min) compared to the control tablets (16 min) for PRC resulting in significantly 628 
faster drug dissolution (85% of drug dissolved at 20 min for the MgStL variant tablets compared 629 
to 70% of drug dissolved at 20 min for the control tablets) (REAUC = 65%), that could be 630 
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attributed to the lower tablet hardness of the MgStL variant tablets (Table 3). Differences in 631 
tablet disintegration (9 min) and drug dissolution (9% of drug dissolved at 20 min) between 632 
the MgStL variant tablets and the control tablets were not observed in the case of CBZ, 633 
presumably due to the hardness of the CBZ tablets was not affected when decreasing the 634 
particle size of MgSt (Table 3). The RE of excipients on the AUCs of the dissolution profiles 635 
for CBZ was close to the lower limit of the reference range criterion (REAUC = -21%) indicating 636 
that slight differences in drug dissolution may be expected at early time points when varying 637 
MgSt. The real-time dissolution UV imaging studies confirmed that for immediate release 638 
formulations, excipients may alter drug dissolution due to their effects on tablet disintegration 639 
and/or tablet wetting. The impact of excipient variability on drug dissolution depends both on 640 
excipient and drug characteristics as significant differences were mainly observed for PRC 641 
when varying the MgSt brand and CBZ when varying the HPMC brand. The disintegration 642 
data from the real-time dissolution UV images were longer but in a similar rank order as 643 
compared to the data from the compendial disintegration test (Table 3). The results reveal that 644 
real-time dissolution UV imaging provides additional insights on tablet disintegration and drug 645 
dissolution in a biorelevant perspective through the visualization of the dissolution process. 646 
3.4. Correlation of drug solubility and drug dissolution performance in 647 
presence of excipients 648 
The REs of excipients on the AUCs of the dissolution profiles of the variant tablets as a 649 
function of the RE of the excipients on drug solubility in compendial and biorelevant media 650 
are presented in Figure 9. In cases where significant changes in drug solubility were not 651 
observed when varying excipient brands (-20% < REsS < 25%), drug dissolution was not 652 
greatly affected by excipient variability, as indicated by the low REs of excipients on the AUCs 653 
of the dissolution profiles (-20% < REsAUC < 25%). In cases where excipient variability 654 
significantly altered drug solubility, drug dissolution was affected by the excipient change and 655 
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depended on the applied hydrodynamics. This was the case for PRC in the presence of MgSt, 656 
where the low particle size brand (Ligamed MF-3-V) decreased the apparent drug solubility to 657 
a higher extent as compared to the high particle size brands (Ligamed MF-2-V). This was 658 
attributed to i. the higher lubrication efficiency of the low particle size brand around drug 659 
particles or ii. drug shielding by the presence of a more lipophilic MgSt brand. The faster drug 660 
dissolution relates to the low particle size of the MgStL variant brand (Ligamed MF-3-V) which 661 
due to its improved lubrication efficiency produced softer tablets. As the hardness of the CBZ 662 
control tablets was lower compared to the PRC (Table 3), the impact of varying MgSt brand 663 
was not pronounced for the poorly soluble compound. Differences in the dissolution profiles 664 
of PRC when varying MgSt brand were more pronounced in the USP 2 apparatus and USP 4 665 
apparatus – small cell (20% < REsAUC < 41%) compared to the USP 4 apparatus – large cells 666 
(REsAUC < 20%) due to the differences in the applied hydrodynamics, as explained previously 667 
(section 3.4.1). For the highly soluble drug, in the cases where an average correlation between 668 
the impact of excipients on drug dissolution and drug solubility was observed (REAUC ≈ 20%, 669 
close to the upper limit of risk assessment criteria), dissolution profile comparisons can still 670 
prove differences in drug dissolution (Table 4). The aforementioned correlations indicate that 671 
drug solubility studies can give an insight on the impact of excipient variability on drug 672 
dissolution, as for the majority of cases the effects of excipients on drug dissolution and drug 673 
solubility were well correlated, apart from the case of PRC dissolution in the USP 4 apparatus 674 
(large cells) when varying MgSt (no significant changes in drug dissolution attributed to the 675 
low fluid velocities of the system [71]). 676 
3.5. Multivariate data analysis of in vitro dissolution data 677 
The standardized beta coefficients of the variables in compendial and biorelevant media 678 
are presented in Figure 10. The two models showed a good predictive power and fit 679 
(compendial media: Q2 = 0.5, R2 = 0.6, biorelevant media: Q2 = 0.5, R2 = 0.6). The statistical 680 
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analysis reveals that the impact of excipient variability on drug dissolution depends on the 681 
excipient variant. MgStL variant (compendial media, positive effect, VIP = 1.7, biorelevant 682 
media, positive effect, VIP = 1.6) was a significant variable in both models revealing that faster 683 
drug dissolution can be anticipated from tablets containing MgSt of low particle size due to the 684 
production of softer tablets with faster tablet disintegration as compared to tablets containing 685 
MgSt of high particle size. The SSGL variant (compendial media: negative effect, VIP = 1.3) 686 
and HPMCH variant (biorelevant media: negative effect, VIP = 1.0) were significant variables 687 
in the indicated models. The negative effect of these variables reveals that varying SSG or 688 
HPMC viscosity type may result in slightly slower drug dissolution or that the improvement in 689 
drug dissolution will be lower when varying the aforementioned grades compared to MgSt. 690 
The impact of excipient variability on drug dissolution also related to drug aqueous solubility 691 
as revealed by the significance of the variable Drug(aq.sol.) (positive effect, VIP = 1.2) in the 692 
biorelevant model. This variable indicates that a significantly faster drug dissolution when 693 
varying excipient types is anticipated for the highly soluble drug, as excipient variability may 694 
strongly affect tablet properties of hydrophilic components (Table 3). The significance of the 695 
variable Drug(aq.sol.) in biorelevant (and not in compendial) media indicates that changes in drug 696 
dissolution will be pronounced in media where tablets disintegrate rapidly, due to the presence 697 
of the solubilizing components which improve tablet wetting [8]. The effects of excipient on 698 
drug dissolution depends also on the hydrodynamics, as revealed by the significance of the 699 
USP 4 hydrodynamics (compendial media: negative effect, VIP 1.3, biorelevant media: 700 
negative effect, VIP = 1) in both models. This variable indicates that the improvement in drug 701 
dissolution by the studied excipients in the USP 4 apparatus may be less pronounced when the 702 
large cells are used, as differences in drug dissolution rates cannot be observed in very low 703 
fluid velocities [71]. 704 
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The complex nature of excipient variability and its impact on drug dissolution was 705 
identified by the significance of certain interactions between the studied variables. MgStL 706 
variant* Drug(aq.sol.) was a significant variable (compendial media: positive effect, VIP = 2.1, 707 
biorelevant media: positive effect, VIP = 2.4) in both models and reveals that the enhancement 708 
in drug dissolution by low particle size MgSt brands will be pronounced for highly soluble 709 
drugs (due to the differences in tablet hardness). SSGL variant* Drug(aq.sol.) (compendial media: 710 
negative effect, VIP = 1.7, biorelevant media: negative effect, VIP = 1.3) and HPMCH variant* 711 
Drug(aq.sol.) (biorelevant media: negative effect, VIP = 1.0) were significant interactions in the 712 
models. These interactions reveal that the enhancement in drug dissolution when varying SSG 713 
or HPMC viscosity will be less pronounced for the highly soluble drug, as, generally, presence 714 
of hydrophilic excipients may improve the dissolution of poorly soluble drugs. Finally, SSGL 715 
variant*hydrodynamics (negative effect, VIP = 1.0) was a significant variable in the 716 
compendial model revealing that varying SSGL variant may result in slightly slower drug 717 
dissolution or that the improvement in drug dissolution will be lower with decreasing flow 718 
velocities [71, 72]. 719 
4.  Conclusions 720 
Dissolution testing plays a key role in QbD approaches assessing the quality and 721 
biorelevant or clinical performance of final dosage forms. Excipient presence and variability 722 
may present challenges for oral drug absorption, therefore understanding the 723 
biopharmaceutical implications of excipients on product performance with the use of 724 
dissolution tests is beneficial. To-date, attention is drawn on excipients with potential effects 725 
on drug permeability (surfactants, absorption enhancers); simple excipients, however, may as 726 
well be problematic in terms of product performance. In this work, the impact of excipient 727 
variability of binders (HPMC – viscosity type), superdisintegrants (SSG – viscosity type) and 728 
lubricants (MgSt – PSD type) on the dissolution of a highly and a poorly soluble drug from 729 
31 
 
immediate release formulations was assessed in a biopharmaceutical perspective. Varying 730 
MgSt brand was identified as potentially critical for oral drug performance as faster dissolution 731 
was observed for the highly soluble drug due to the production of softer tablets when decreasing 732 
the particle size of MgSt. This finding tackles fundamental aspects of the impact of excipients 733 
on product performance and reveals further biopharmaceutical excipient implications on drug 734 
dissolution. Dissolution profile comparisons revealed that MgStL variant tablets would not 735 
meet the quality control acceptance criteria and could present regulatory implications. The 736 
impact of hydrodynamics on the effects of MgSt variability on drug dissolution was revealed, 737 
as increasing flow velocities (for the highly soluble drug) resulted in dissolution methods with 738 
better discriminatory power. Varying HPMC or SSG grade was of low criticality for product 739 
performance as similarity was found between the dissolution profiles of the control and variant 740 
tablets irrespective of the model compound. The pH and presence of solubilizing components 741 
affected the impact of excipients (especially SSG and MgSt) on drug dissolution. Real-time 742 
dissolution UV imaging revealed that varying excipient types/brands can affect tablet 743 
disintegration and/or wetting and offered additional opportunities in terms of identifying 744 
excipient effects in drug dissolution (as compared to the standard pharmacopeial tests). In vitro 745 
dissolution data were in good agreement with previous solubility studies in presence of 746 
excipients showing that changes in drug solubility by excipient variability may indicate 747 
significant changes in drug dissolution. Use of PLS revealed the significant role of excipient 748 
type and material attributes, drug aqueous solubility, medium characteristics and 749 
hydrodynamic conditions on the excipient effects on drug dissolution. The study highlights the 750 
effects of excipient variability on product performance and the importance of 751 
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Table 1: Composition of the manufactured tablets 995 
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Table 2: Parameters evaluated with multivariate data analysis 998 
Parameter Level 
 0 1 
Drug(aq.sol.)* Poorly soluble Highly soluble 
Medium Gastric Intestinal 
Hydrodynamics USP 2 apparatus USP 4 apparatus 
USP 4 hydrodynamics Small cells Large cells 
HPMCH variant HPMC – low viscosity HPMC – high viscosity 
SSGL variant SSG – high viscosity SSG – low viscosity 
MgStL variant MgSt –high PSD** MgSt – low PSD 
* Drug(aq.sol) = Drug aqueous solubility, **PSD = particle size distribution 999 
45 
 








































































































Table 4: Similarity factors (f2) of the dissolution profile comparisons for PRC and CBZ variant 1002 
tablets in compendial and biorelevant media using the USP 2 and USP 4 (small and large cells) 1003 
apparatuses. Bold values indicate significant differences between the test and the reference 1004 
dissolution profiles (f2 < 50). 1005 
    Compendial Media Biorelevant Media 
    
0.1 N HCl pH 
1 
Phosphate 
buffer pH 6.8 
FaSSGF FaSSIF-V2 





62.9 83.8 67.2 70.9 59.5 76.3 85.4 86.2 
SSGL 
Variant 
69.7 63.6 64.4 67.3 65.0 65.4 83.6 76.7 
MgStL 
Variant 







55.8 58.8 72.0 56.4 83.5 67.6 71.6 62.1 
SSGL 
Variant 
77.7 64.2 62.6 56.8 70.3 59.1 72.3 61.2 
MgStL 
Variant 







65.6 -* 81.5 - 88.9 - 64.6 - 
SSGL 
Variant 
66.1 - 80.9 - 91.8 - 87.8 - 
MgStL 
Variant 
58.2 - 61.6 - 63.0 - 56.0 - 
*experiments not performed1006 
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Figure captions 1007 
Figure 1: Cumulative % dissolved of PRC from tablet formulations in compendial and biorelevant media using the a. USP 2 apparatus (500 mL, 1008 
50 rpm, 37°C), b. USP 4 apparatus (closed mode, small cells, 500 mL, 4 mL/min, 37°C) and c. USP 4 apparatus (closed mode, large cells, 500 1009 
mL, 4 mL/min, 37°C). The different tablets are shown as: i. control tablets (black circles), ii. HPMCH variant tablets (blue diamonds), iii. SSGL 1010 
variant tablets (green triangles) and iv. MgStL variant tablets (red squares). (Mean ± SD, n = 3) 1011 
Figure 2: Relative effects of excipients on the AUCs of the dissolution profiles between acidic and basic conditions for PRC and CBZ from the 1012 
control tablets in compendial (green colour) and biorelevant (blue colour) media. (Mean ± SD, n = 3) 1013 
Figure 3: Cumulative % dissolved of CBZ from tablet formulations in compendial and biorelevant media using the a. USP 2 apparatus (500 mL, 1014 
50 rpm, 37°C) and b. USP 4 apparatus (open mode, small cells, 4 mL/min, 37°C). The different batches are shown as: i. control tablets (black 1015 
circles, ii. HPMCH variant tablets (blue diamonds), iii. SSGL variant tablets (green triangles) and iv. MgStL variant tablets (red squares). (Mean ± 1016 
SD, n = 3) 1017 
Figure 4: a. Relatives effects of excipients on the AUCs of the dissolution profiles between the control and HPMCH variant tablets for the 1018 
dissolution of PRC and CBZ in compendial (green colour) and biorelevant (blue colour) media in the studied apparatuses. Light and dark colours 1019 
correspond to acidic and basic conditions, respectively (Mean ± SD, n = 3). b. Relative effects of excipients on the AUCs of the dissolution profiles 1020 
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between acidic and basic conditions for the dissolution of PRC and CBZ from the HPMCH variant tablets in compendial (green colour) and 1021 
biorelevant (blue colour) media. (Mean ± SD, n = 3) 1022 
Figure 5: a. Relatives effects of excipients on the AUCs of the dissolution profiles between the control and SSGL variant tablets for the dissolution 1023 
of PRC and CBZ in compendial (green colour) and biorelevant (blue colour) media in the studied apparatuses. Light and dark colours correspond 1024 
to acidic and basic conditions, respectively. (Mean ± SD, n = 3). b. Relative effects of excipients on the AUCs of the dissolution profiles between 1025 
acidic and basic conditions for the dissolution of PRC and CBZ from the SSGL variant tablets in compendial (green colour) and biorelevant (blue 1026 
colour) media. (Mean ± SD, n = 3) 1027 
Figure 6: a. Relatives effects of excipients on the AUCs of the dissolution profiles between the control and MgStL variant tablets for the dissolution 1028 
of PRC and CBZ in compendial (green colour) and biorelevant (blue colour) media in the studied apparatuses. Light and dark colours correspond 1029 
to acidic and basic conditions, respectively (Mean ± SD, n = 3). b. Relative effects of excipients on the AUCs of the dissolution profiles between 1030 
acidic and basic conditions for the dissolution of PRC and CBZ from the MgStL variant tablets in compendial (green colour) and biorelevant (blue 1031 
colour) media. (Mean ± SD, n = 3) 1032 
Figure 7: Real-time surface dissolution UV images for a. PRC and b. CBZ tablets in 0.1 N HCl pH 1. 1033 
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Figure 8: Dissolution profiles of PRC and CBZ from the i. Control tablets (black circles), ii. HPMCH variant tablets (blue diamonds), iii. SSGL 1034 
variant tablets (green triangles) and iv. MgStL variant tablets (red squares) in 0.1 N HCl pH 1 using surface dissolution UV Imaging (SDi2, 6.16 1035 
mL/min, 37 °C, open mode). (Mean ± SD, n = 3) 1036 
Figure 9: Relative effects of the studied excipients on the AUCs of the dissolution profiles (REAUC) as a function of relative effects of the studied 1037 
excipients on drug solubility (RES) in a. compendial and b. biorelevant media. The excipient types are presented as: i. HPMC (circles), ii. SSG 1038 
(squares) and iii. MgSt (diamonds). The drugs are portrayed as: i. PRC (filled symbols) and ii. CBZ (empty symbols). The dissolution profiles 1039 
with the studied apparatuses are shown as: i. USP 2 apparatus (blue colour), ii. USP 4 apparatus – small cells (red colour) and iii. USP 4 apparatus 1040 
- large cells (green colour). (Mean ± SD, n = 3) 1041 
Figure 10: Standardized coefficients of the studied variables (and interaction terms) in compendial (blue colour) and biorelevant (red colour) 1042 
media. * denotes coefficients of VIP > 1. * denotes coefficients of 0.8 < VIP < 1. (Mean, - SE)1043 
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Figure 10 1062 
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 1064 
